Search PubMed⌕ Search

Biomedical subjects

W Linkesch

Publications and source records attributed to W Linkesch.

At least 109 records · Page 6Linked to original sources

Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.

Several side-effects of asparaginase therapy have been said to be a consequence of the glutaminase activity of Escherichia coli asparaginase, especially the deleterious influence on the liver function. We report here the drug-induced impairments of asparagine and glutamine metabolism in correlation to concentrations changes of plasma proteins, synthesized in the liver, in patients with acute lymphatic leukaemia. One hour after asparaginase application, plasma glutamine decreased to 5% (0-39%: median, range) of the initial values, with a subsequent rise to concentrations slightly lower than those prior to therapy. During the 14 days of drug application the fasting plasma concentrations of glutamine fell to a median of 63% of the pre-therapeutic levels, indicating a depletion of the glutamine pools. Two days after the end of asparaginase application, in one patient the glutamine concentrations increased to the pre-therapeutic range. Plasma concentrations of fibrinogen and antithrombin III decreased to 46% and 56%, respectively, of the initial values, with a slight increase 2 days after the end of therapy. The changes of plasma protein concentrations followed the course of plasma glutamine and asparagine. From that we deduce that the hepatic synthesis of the plasma proteins might be influenced by asparagine and glutamine depletion as a consequence of the therapy with E. coli asparaginase.

Amino Acids↗

[Interferon therapy in multiple myeloma].

Natural leukocyte interferon and recombinant interferon alpha-2 have effected remission rates between 10 and 20% in the treatment of multiple myeloma. Response rates have been higher in untreated patients than in relapsing or primarily refractory cases. Patients with slowly proliferating tumors, early tumor stage or IgA-monoclonal protein seem to show increased sensibility to interferon as compared to patients without those characteristics. First trials using combined interferon chemotherapy regimens suggest that the toxicity associated with this treatment modality remains acceptable. At present, however, one cannot definitely decide whether and to which degree the combination therapy will improve the response rates.

Antineoplastic Combined Chemotherapy Protocols↗

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.

During previous therapeutic trials with interferon, decreased levels of peripheral platelet counts have been observed. Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. A total of 15 patients with polycythemia vera, essential thrombocytosis, or chronic myeloid leukemia received rec-IFN-alfa at initial doses of 25-70 x 10(6) units/week; maintenance therapy following week 8 of treatment consisted of 20-35 x 10(6) units/week rec-IFN. Observation periods ranged from 24 to 48 weeks. Significant reductions in the number of platelets were noted in all cases; 12/15 patients achieved platelet counts below 440 x 10(9)/l and maintained those normal values for at least 4 weeks. The number of bone marrow megakaryocytes, which had been increased prior to treatment, diminished during rec-IFN therapy, while the previously shortened platelet half-life further decreased with rec-IFN treatment. During rec-IFN-induced remission, the plasma levels of platelet factors, the activity of natural killer cells, and platelet aggregation showed changes between slight improvement and normal values. Severe side effects were only observed with the highest rec-IFN doses; dosage adjustments were effective in improving or eliminating all treatment-related symptoms. Rec-IFN may prove to be a valuable therapeutic alternative to cytostatic treatment of thrombocytosis in myeloproliferative disorders.

Aged↗

Serum iron status in Rett syndrome.

Low ferritin content in putamen and frontal cortex found in a postmortem study in a single case of Rett syndrome prompted measurement of iron-related parameters in blood. Serum ferritin, serum iron and transferrin were evaluated in 27 patients with classical Rett syndrome. Signs of iron deficiency and depletion of body iron stores were found in 20% of probands aged up to 6 years and in 37% older than 14 years. This result is in accordance with figures from the normal female population and therefore a linkage between iron depletion in brain and depleted iron stores could not be proven.

Adolescent↗

Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells.

A short-term test in vitro is described, which can be used to detect resistance to cytostatic agents in leukaemic cells. Leukaemic cell suspensions were incubated with cytostatic agents and the resulting intracellular ATP concentrations were measured by a bioluminescence ATP assay. There was a clear dose-effect relationship in acute leukaemia and chronic lymphocytic leukaemia cells for drugs used in the treatment of leukaemias. A good correlation was found between the ATP content of leukaemic cells and cell viability as determined by the trypan blue dye exclusion test. Preliminary individual clinical correlations suggest a correlation between the chemosensitivity in vitro and the response patterns in vivo in leukaemia patients. This simple, fast and sensitive method may have application for determination of drug-induced cytotoxicity in leukaemic cells in vitro.

Acute Disease↗

CSF cytology of a patient with conversion of an acute lymphatic leukemia to an acute eosinophilic leukemia.

The course of leukemic disease in a male adolescent with meningeal leukemia is described. The bone marrow aspirates showed a conversion from an acute lymphatic leukemia to an eosinophilic leukemia. Four weeks after the peripheral shift of phenotype two different cell clones were detected in one CSF smear. While under ultrahigh dose araC therapy the patient died 3 months after conversion. Possible explanation for the shift of phenotype and the peculiar leptomeningeal infiltration are discussed.

Adolescent↗

Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia.

Blast cells from 45 patients with chronic myeloid leukaemia in blast crisis (CML-BC) were immunologically phenotyped with a panel of 26 monoclonal antibodies and studied for terminal deoxynucleotidyl transferase (TdT) content. Out of 45 blast-populations, 28 showed a myeloid, 14 a lymphoid, two a mixed and one an unclassifiable marker profile. In contrast to acute myeloid leukaemia (AML), we found frequent involvement of the thrombopoietic and erythropoietic systems in myeloid CML-BC. Furthermore, the marker profile on blast cells in myeloid CML-BC was different from that seen in AML. The blast cells in lymphoid blast crises of CML displayed the same lymphoid marker profile as those in acute lymphoblastic leukaemia. In three of 16 patients who were serially tested, we observed phenotypic changes in the blast cell populations. In one patient the blasts changed from lymphoid to myeloid type while remaining TdT-positive; in another case the blasts switched from granulomonocytic TdT-negative to granulomonocytic TdT-positive. In the third patient erythroid precursor cells appeared as the disease progressed. The results indicate the capacity of blast populations in CML-patients during blast crisis to differentiate along several pathways.

Adolescent↗

Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.

Forty-two patients with multiple myeloma were allocated to two groups to receive either polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone, or recombinant interferon-alpha 2C monotherapy. The response rate of 43% in the interferon group was significantly lower than that in the chemotherapy group (89%). Patients with stage I disease showed better response rates than those with stage II or stage III disease. Eleven patients with thrombocythaemia due to polycythaemia vera, chronic myeloid leukaemia or essential thrombocythaemia were treated with recombinant interferon-alpha 2C and complete remissions were achieved in 7 of the 8 evaluable patients. Side-effects were common on interferon therapy, but could be reduced by dose reduction and were reversed by cessation of treatment.

Adult↗

Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.

Serum ferritin levels, cumulative number of administered blood transfusions, number of monthly transfused blood units and total months on hemodialysis (HD) treatment differed significantly in 7 patients on hemodialysis with clinical, biochemical and histological evidence of hemosiderosis, when compared to 37 controls (p less than 0.001 for all parameters). As a new treatment method desferrioxamine (DFO) therapy was introduced for iron detoxification in these hemosiderotic chronically hemodialyzed patients. Hence, to maximize the biological half-time, 30 mg/kg body weight DFO were given after the end of HD in the iron-loaded patients. Iron removal during the subsequent HD and the increase of iron excretion by the stool after DFO was measured by atomic absorption spectroscopy. Iron removal by the artificial kidney was calculated by investigating the function (QDi + QF)CDo over the duration of HD treatment, which equals the total amount of iron removal during HD. Using numerical integration of measured data this removal was found to be 21.8 +/- 6.9 mg whereas cumulative iron loss via the feces was found to be 36.5 +/- 14.6 mg. Therefore, total iron elimination was calculated to be on average 50-60 mg after administration of a single dose of DFO. Furthermore, long-term treatment of 5 patients resulted in a significant decrease of serum ferritin levels from 2,309 +/- 295 to 715 +/- 177 ng WHO/ml (p less than 0.001) after a period of 36 +/- 5 months. We conclude, that DFO in a dosage of 30 mg/kg body weight given at the end of HD is able to remove more than 500 mg iron/month if it is administered following each HD. Long-term results indicate negative iron balance without significant change of transfusion frequency if not more than 2 U of blood (500 mg iron) are administered within 1 month. This treatment schedule might be superior compared to the previously used methods of administration where DFO was given at the beginning or throughout HD.

Adolescent↗

[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].

15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.

Aged↗

[Serum ferritin--its diagnostic relevance and clinical significance].

The introduction of a WHO Standard for serumferritin effected a standardisation of different methods, improving quality and security for clinical routine diagnostic purposes. Therefore the clinical evaluation of serumferritin gained even more importance. For Evaluation of iron stores of children, pregnant women, population studies, patients on hemodialysis or patients with rheumatoid arthritis low serumferritin values give safe results. In addition serumferritin is of clinical usefulness in monitoring therapy of both iron deficiency and iron overload. Evaluating a single serumferritin value one should consider the total clinical situation of the patient. As some tumors can produce and secrete serumferritin, e. g. acute myeloblastic leukemia, germ cell tumors, malignant melanoma, serumferritin might be helpful in monitoring the malignant disease. The ongoing characterization of tissue isoferritin, especially acidic isoferritin, may eventually lead to a clinically significant diagnostic marker of neoplasia.

Adult↗

Serial determination of serum ferritin levels in patients with malignant melanoma.

In a pilot study, serum ferritin levels of patients with malignant melanoma were found to be increased in stage III of the disease. Therefore, serial determinations were carried out up to 24 months in patients at various stages of the disease undergoing either chemo- or immunotherapy. Serum ferritin was determined by a two-site IRMA technique. Serum samples of 91 patients in different clinical stages of histologically verified malignant melanoma were included in these investigations. 80 healthy individuals were also investigated to determine normal ranges of serum ferritin. In stage III serum ferritin levels were significantly elevated (p less than 0,0005), whereas in stages I and II the values were within the normal range. Repeated serum ferritin levels of 10 patients in stage I and 13 patients in stages II and III without evidence of tumor progression were within the normal range. In 9 patients in stage III the increases in serum ferritin concentration correlated with the degree of dissemination of metastasis. Because of the occurrence of increased ferritin levels only in melanoma patients with progressive metastatic disease, the measurement of serum ferritin might have limited utility in clinical evaluation of melanoma patients as well as in the prediction of recurrence and in monitoring response to therapy.

Female↗

[Not Available].

Explore the source record for details and available documents.

Czechoslovakia↗

Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.

In 76 patients with clinically well-defined multiple myeloma (median age at diagnosis: 68.5 years), serum ferritin (SF) and beta 2-microglobulin (beta 2M) were measured by RIA methods. Seventy sex- and age-matched healthy individuals served as controls. Both serum ferritin (median: 343 vs 193 micrograms/liter; P less than 10(-7] and beta 2M (median: 4.25 vs 3.5 mg/liter) showed a significant increase (P less than 0.05) in myeloma patients compared to controls. Intercorrelation analysis revealed significant correlations between SF and tumor mass, serum creatinine, and beta 2M, and between beta 2M and tumor mass, percentage of plasma cell infiltration in bone marrow, agglutinine titers, serum creatinine, hemoglobin, and age of the patients. Both tumor proteins might gain clinical importance particularly in those patients in which precise monitoring of disease is impossible either due to lack of paraprotein production or due to the particular paraprotein type. This seems to account for patients with light chain paraproteins, and for those patients with biclonal gammopathies or with IgE and/or IgD paraproteins.

Adult↗

[Serum-alpha 1-fetoprotein and serumferritin in liver tumours (author's transl)].

Serum-alpha 1-fetoprotein (AFP) and serumferritin were evaluated in 22 patients with hepatocellular carcinomas as well as in 25 patients with metastatic liver cancer. In all cases the diagnosis was established histologically. 21 out of all patients (95.4%) with hepatocellular carcinomas had increased AFP values (greater than 9 ng/ml), but only 18 (81.8%) had increased AFP values, which were highly suggestive of hepatoma (greater than 174 ng/ml). 17 out of 22 patients (77.2%) with malignant hepatomas had increased serumferritin levels ((greater than 343 ng/ml). In 4 patients (18.2%) with hepatocellular carcinomas, which had uncharacteristically low AFP values, increased serumferritin levels indicated malignoma. In patients with metastatic liver cancer AFP was increased in 7 (28%). Serumferritin levels were increased in 22 out of 25 patients (88%). Combining the results of these two tumour markers detection of liver cancer can be increased highly. However, serumferritin has to be regarded as an unspecific tumour marker, which does not allow a differentialdiagnosis between primary liver cancer and metastatic liver cancer.

Carcinoma, Hepatocellular↗